BACE1 inhibitors

US11034687B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11034687-B2
Application numberUS-202016903616-A
CountryUS
Kind codeB2
Filing dateJun 17, 2020
Priority dateMar 20, 2015
Publication dateJun 15, 2021
Grant dateJun 15, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of formula I: wherein: A is isoxazolyl or triazolyl; B is a heteroaryl group; R 1 is selected from the group consisting of i) C 1-6 -alkyl and ii) halogen-C 1-6 -alkyl; R 2 is selected from the group consisting of i) C 1-6 -alkyl, and ii) halogen-C 1-6 -alkyl; or R 1 and R 2 form together with the C-atom they are attached to, a C 3-6 -cycloalkyl-, wherein the C 3-6 -cycloalkyl- is optionally substituted by one or more substituents selected from the group consisting of halogen and hydroxyl; R 3 is selected from the group consisting of i) hydrogen, ii) C 3-6 -cycloalkyl, iii) halogen-C 1-6 -alkyl, and iv) C 1-6 -alkyl; R 4 is selected from the group consisting of i) hydrogen, and ii) C 1-6 -alkyl; R 5 is selected from the group consisting of i) C 1-6 -alkyl, and ii) halogen-C 1-6 -alkyl; R 6 is halogen; and R 7 is selected from the group consisting of i) amino, ii) cyano, iii) hydrogen, iv) OH, v) halogen, vi) C 1-6 -alkyl, vii) C 1-6 -alkyl-C 3-6 -cycloalkyl, viii) halogen-C 1-6 -alkyl, ix) C 1-6 -alkoxy-C 1-6 -alkyl, x) C 2-6 -alkynyl, xi) C 2-6 -alkynyl-C 1-6 -alkyl, xii) C 2-6 -alkynyl-C 1-6 -alkoxy xiii) C 1-6 -alkoxy, and xiv) halogen-C 1-6 -alkoxy; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 , which is of formula Ia, wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is as defined in claim 1 : or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1 , wherein B is a 6-membered heteroaryl group. 4. The compound according to claim 1 , wherein B is pyrazinyl, pyrimidinyl or pyridinyl. 5. The compound according to claim 1 , wherein R 1 is C 1-6 -alkyl. 6. The compound according to claim 1 , wherein R 1 is methyl. 7. The compound according to claim 1 , wherein R 2 is C 1-6 -alkyl. 8. The compound according to claim 1 , wherein R 2 is methyl. 9. The compound according to claim 1 , wherein R 1 and R 2 form together with the C-atom they are attached to a C 3-6 -cycloalkyl-. 10. The compound according to claim 1 , wherein R 1 and R 2 form together with the C-atom they are attached to a cyclopentyl. 11. The compound according to claim 1 , wherein R 3 is H, CH 3 , CD 3 , CH 2 CF 3 or cyclopropyl. 12. The compound according to claim 1 , wherein R 3 is C 1-6 -alkyl. 13. The compound according to claim 1 , wherein R 3 is methyl. 14. The compound according to claim 1 , wherein R 4 is hydrogen. 15. The compound according to claim 1 , wherein R 5 is C 1-6 -alkyl or halogen-C 1-6 -alkyl. 16. The compound according to claim 1 , wherein R 5 is methyl or —CH 2 F. 17. The compound according to claim 1 , wherein R 6 is F. 18. The compound according to claim 1 , wherein R 7 is Br, CH 2 -cyclopropyl, Cl, CN, Et, Me, OCH 2 CF 2 CHF 2, OCH 2 CF 3, OCH 2 CHF 2, OH or OMe.

Assignees

Inventors

Classifications

  • C07D417/14Primary

    containing three or more hetero rings · CPC title

  • for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

  • Non-condensed thiazines containing further heterocyclic rings · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11034687B2 cover?
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
Who is the assignee on this patent?
Hoffmann La Roche
What technology area does this patent fall under?
Primary CPC classification C07D417/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).